Les complications varient-elles selon la substance ?
Oui, les complications dépendent de la nature de la substance et de la dose reçue.
VariabilitéSubstancesComplications
#5
Quels sont les risques de réexposition ?
La réexposition peut aggraver les complications et augmenter le risque de maladies chroniques.
RéexpositionRisquesMaladies chroniques
Facteurs de risque
5
#1
Quels sont les facteurs de risque d'intoxication ?
Les facteurs incluent l'âge, le sexe, l'état de santé et l'environnement de travail.
Facteurs de risqueÂgeEnvironnement de travail
#2
Les travailleurs sont-ils plus à risque ?
Oui, les travailleurs exposés à des produits chimiques sont souvent à risque accru d'intoxication.
TravailleursExpositionIntoxication
#3
Comment l'âge influence-t-il le risque d'intoxication ?
Les jeunes enfants et les personnes âgées sont plus vulnérables aux effets toxiques.
ÂgeVulnérabilitéToxicité
#4
Les maladies préexistantes augmentent-elles le risque ?
Oui, certaines maladies peuvent rendre les individus plus sensibles aux effets toxiques.
Maladies préexistantesSensibilitéToxicité
#5
L'environnement joue-t-il un rôle dans l'intoxication ?
Oui, un environnement pollué ou des conditions de travail dangereuses augmentent le risque.
EnvironnementPollutionConditions de travail
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Dose létale 50 : Questions médicales les plus fréquentes",
"headline": "Dose létale 50 : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Dose létale 50 : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-21",
"dateModified": "2025-04-16",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Dose létale 50"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Relation dose-effet des médicaments",
"url": "https://questionsmedicales.fr/mesh/D004305",
"about": {
"@type": "MedicalCondition",
"name": "Relation dose-effet des médicaments",
"code": {
"@type": "MedicalCode",
"code": "D004305",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "G07.690.936.500"
}
}
},
"about": {
"@type": "MedicalCondition",
"name": "Dose létale 50",
"alternateName": "Lethal Dose 50",
"code": {
"@type": "MedicalCode",
"code": "D007928",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Xia Yang",
"url": "https://questionsmedicales.fr/author/Xia%20Yang",
"affiliation": {
"@type": "Organization",
"name": "Department of Pediatrics, The First Affiliated Hospital of Guangxi Medical University, No. 6, Shuangyong Road, 530021, Nanning, Guangxi Zhuang Autonomous Region, China."
}
},
{
"@type": "Person",
"name": "Hirofumi Kurose",
"url": "https://questionsmedicales.fr/author/Hirofumi%20Kurose",
"affiliation": {
"@type": "Organization",
"name": "Department of Urology, Chikugo City Hospital, Chikugo, Japan."
}
},
{
"@type": "Person",
"name": "Keisuke Komiya",
"url": "https://questionsmedicales.fr/author/Keisuke%20Komiya",
"affiliation": {
"@type": "Organization",
"name": "Department of Urology, Kurume University School of Medicine, Kurume, Japan."
}
},
{
"@type": "Person",
"name": "Naoyuki Ogasawara",
"url": "https://questionsmedicales.fr/author/Naoyuki%20Ogasawara",
"affiliation": {
"@type": "Organization",
"name": "Department of Urology, Kurume University School of Medicine, Kurume, Japan."
}
},
{
"@type": "Person",
"name": "Kosuke Ueda",
"url": "https://questionsmedicales.fr/author/Kosuke%20Ueda",
"affiliation": {
"@type": "Organization",
"name": "Department of Urology, Kurume University School of Medicine, Kurume, Japan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Online parent training platform for complementary treatment of disruptive behavior disorders in attention deficit hyperactivity disorder: A randomized controlled trial protocol.",
"datePublished": "2022-10-27",
"url": "https://questionsmedicales.fr/article/36301983",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1371/journal.pone.0272516"
}
},
{
"@type": "ScholarlyArticle",
"name": "Examining attention-deficit/hyperactivity disorder and related behavioral disorders by fertility treatment exposure in a prospective cohort.",
"datePublished": "2023-03-25",
"url": "https://questionsmedicales.fr/article/36972758",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.annepidem.2023.03.006"
}
},
{
"@type": "ScholarlyArticle",
"name": "Attachment in adolescents with attention deficit hyperactivity disorder and oppositional defiant disorder.",
"datePublished": "2022-06-30",
"url": "https://questionsmedicales.fr/article/36342984",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.12740/PP/OnlineFirst/130366"
}
},
{
"@type": "ScholarlyArticle",
"name": "The functioning of families of teens with attention deficit hyperactivity disorder and oppositional defiant disorder.",
"datePublished": "2022-08-31",
"url": "https://questionsmedicales.fr/article/37074835",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.12740/PP/OnlineFirst/128372"
}
},
{
"@type": "ScholarlyArticle",
"name": "Understanding Attentional Functioning in Adult Attention Deficit Hyperactivity Disorder-Could This Improve Diagnostic Specificity?",
"datePublished": "2023-03-14",
"url": "https://questionsmedicales.fr/article/36981985",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijerph20065077"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Phénomènes physiologiques",
"item": "https://questionsmedicales.fr/mesh/D010829"
},
{
"@type": "ListItem",
"position": 3,
"name": "Phénomènes pharmacologiques et toxicologiques",
"item": "https://questionsmedicales.fr/mesh/D002620"
},
{
"@type": "ListItem",
"position": 4,
"name": "Phénomènes toxicologiques",
"item": "https://questionsmedicales.fr/mesh/D000069436"
},
{
"@type": "ListItem",
"position": 5,
"name": "Relation dose-effet des médicaments",
"item": "https://questionsmedicales.fr/mesh/D004305"
},
{
"@type": "ListItem",
"position": 6,
"name": "Dose létale 50",
"item": "https://questionsmedicales.fr/mesh/D007928"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Dose létale 50 - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Dose létale 50",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-13",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Dose létale 50",
"description": "Comment évaluer la DL50 d'une substance ?\nQuels tests sont utilisés pour mesurer la DL50 ?\nLa DL50 est-elle la même pour tous les organismes ?\nQuels facteurs influencent la DL50 ?\nComment la DL50 est-elle utilisée en recherche ?",
"url": "https://questionsmedicales.fr/mesh/D007928?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Dose létale 50",
"description": "Quels symptômes indiquent une exposition à une DL50 ?\nLes symptômes varient selon la substance ?\nPeut-on prédire les symptômes d'une DL50 ?\nQuels sont les signes d'une intoxication aiguë ?\nComment reconnaître une intoxication par un produit chimique ?",
"url": "https://questionsmedicales.fr/mesh/D007928?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Dose létale 50",
"description": "Comment prévenir l'exposition à des substances toxiques ?\nQuelles sont les mesures de sécurité en laboratoire ?\nLes réglementations aident-elles à prévenir les intoxications ?\nComment éduquer sur les dangers des substances toxiques ?\nLes étiquettes de produits chimiques sont-elles importantes ?",
"url": "https://questionsmedicales.fr/mesh/D007928?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Dose létale 50",
"description": "Quel est le traitement d'une intoxication aiguë ?\nLes antidotes sont-ils toujours efficaces ?\nComment gérer une exposition à une DL50 ?\nQuels soins sont nécessaires après une exposition ?\nLa décontamination est-elle nécessaire ?",
"url": "https://questionsmedicales.fr/mesh/D007928?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Dose létale 50",
"description": "Quelles complications peuvent survenir après une intoxication ?\nLes effets à long terme sont possibles ?\nComment surveiller les complications post-intoxication ?\nLes complications varient-elles selon la substance ?\nQuels sont les risques de réexposition ?",
"url": "https://questionsmedicales.fr/mesh/D007928?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Dose létale 50",
"description": "Quels sont les facteurs de risque d'intoxication ?\nLes travailleurs sont-ils plus à risque ?\nComment l'âge influence-t-il le risque d'intoxication ?\nLes maladies préexistantes augmentent-elles le risque ?\nL'environnement joue-t-il un rôle dans l'intoxication ?",
"url": "https://questionsmedicales.fr/mesh/D007928?mesh_terms=Attention+Deficit+and+Disruptive+Behavior+Disorders#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment évaluer la DL50 d'une substance ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "La DL50 est déterminée par des études sur des groupes d'animaux exposés à différentes doses."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour mesurer la DL50 ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests de toxicité aiguë, souvent sur rongeurs, sont utilisés pour mesurer la DL50."
}
},
{
"@type": "Question",
"name": "La DL50 est-elle la même pour tous les organismes ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, la DL50 varie selon l'espèce, le sexe et l'âge des organismes testés."
}
},
{
"@type": "Question",
"name": "Quels facteurs influencent la DL50 ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "La DL50 peut être influencée par la voie d'exposition, la durée et la sensibilité individuelle."
}
},
{
"@type": "Question",
"name": "Comment la DL50 est-elle utilisée en recherche ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle est utilisée pour comparer la toxicité de différentes substances et établir des normes de sécurité."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent une exposition à une DL50 ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes peuvent inclure des nausées, vomissements, convulsions et coma."
}
},
{
"@type": "Question",
"name": "Les symptômes varient selon la substance ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les symptômes dépendent de la nature de la substance toxique et de la dose."
}
},
{
"@type": "Question",
"name": "Peut-on prédire les symptômes d'une DL50 ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des modèles précliniques peuvent aider à prédire les symptômes, mais il y a des variations."
}
},
{
"@type": "Question",
"name": "Quels sont les signes d'une intoxication aiguë ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les signes incluent des troubles respiratoires, des douleurs abdominales et des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une intoxication par un produit chimique ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "La reconnaissance repose sur l'historique d'exposition et l'apparition rapide des symptômes."
}
},
{
"@type": "Question",
"name": "Comment prévenir l'exposition à des substances toxiques ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Utiliser des équipements de protection, suivre les protocoles de sécurité et éduquer le personnel."
}
},
{
"@type": "Question",
"name": "Quelles sont les mesures de sécurité en laboratoire ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les mesures incluent l'utilisation de hottes, de gants et de formation sur les risques chimiques."
}
},
{
"@type": "Question",
"name": "Les réglementations aident-elles à prévenir les intoxications ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les réglementations sur l'utilisation des produits chimiques aident à réduire les risques."
}
},
{
"@type": "Question",
"name": "Comment éduquer sur les dangers des substances toxiques ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des formations régulières et des affichages d'information peuvent sensibiliser aux dangers."
}
},
{
"@type": "Question",
"name": "Les étiquettes de produits chimiques sont-elles importantes ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, elles fournissent des informations essentielles sur les dangers et les mesures de sécurité."
}
},
{
"@type": "Question",
"name": "Quel est le traitement d'une intoxication aiguë ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Le traitement inclut l'élimination de la substance, le soutien des fonctions vitales et des antidotes si disponibles."
}
},
{
"@type": "Question",
"name": "Les antidotes sont-ils toujours efficaces ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, l'efficacité des antidotes dépend de la substance et du moment de l'administration."
}
},
{
"@type": "Question",
"name": "Comment gérer une exposition à une DL50 ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il faut contacter un centre antipoison et suivre les protocoles d'urgence appropriés."
}
},
{
"@type": "Question",
"name": "Quels soins sont nécessaires après une exposition ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des soins de soutien, une surveillance continue et des traitements spécifiques peuvent être nécessaires."
}
},
{
"@type": "Question",
"name": "La décontamination est-elle nécessaire ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la décontamination est souvent nécessaire pour réduire l'absorption de la substance toxique."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir après une intoxication ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent des lésions organiques, des troubles neurologiques et des infections."
}
},
{
"@type": "Question",
"name": "Les effets à long terme sont possibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines substances peuvent causer des effets à long terme, comme des cancers ou des troubles chroniques."
}
},
{
"@type": "Question",
"name": "Comment surveiller les complications post-intoxication ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une surveillance médicale régulière est nécessaire pour détecter les complications précoces."
}
},
{
"@type": "Question",
"name": "Les complications varient-elles selon la substance ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications dépendent de la nature de la substance et de la dose reçue."
}
},
{
"@type": "Question",
"name": "Quels sont les risques de réexposition ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "La réexposition peut aggraver les complications et augmenter le risque de maladies chroniques."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque d'intoxication ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, le sexe, l'état de santé et l'environnement de travail."
}
},
{
"@type": "Question",
"name": "Les travailleurs sont-ils plus à risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les travailleurs exposés à des produits chimiques sont souvent à risque accru d'intoxication."
}
},
{
"@type": "Question",
"name": "Comment l'âge influence-t-il le risque d'intoxication ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les jeunes enfants et les personnes âgées sont plus vulnérables aux effets toxiques."
}
},
{
"@type": "Question",
"name": "Les maladies préexistantes augmentent-elles le risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies peuvent rendre les individus plus sensibles aux effets toxiques."
}
},
{
"@type": "Question",
"name": "L'environnement joue-t-il un rôle dans l'intoxication ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un environnement pollué ou des conditions de travail dangereuses augmentent le risque."
}
}
]
}
]
}
Department of Pediatrics, The First Affiliated Hospital of Guangxi Medical University, No. 6, Shuangyong Road, 530021, Nanning, Guangxi Zhuang Autonomous Region, China.
Departamento de Farmacoloxía, Farmacia e Tecnología Farmacéutica, Facultade de Veterinaria, Universidade de Santiago de Compostela, Lugo, 27002, Spain. Electronic address: andrea.boente.juncal@usc.es.
Departamento de Farmacoloxía, Farmacia e Tecnología Farmacéutica, Facultade de Veterinaria, Universidade de Santiago de Compostela, Lugo, 27002, Spain. Electronic address: mdelcarmen.vale@usc.es.
Departamento de Fisioloxía, Facultade de Veterinaria, Universidade de Santiago de Compostela, Lugo, 27002, Spain. Electronic address: merchi.camina@usc.es.
Departamento de Anatomía, Producción Animal y Ciencias Clínicas Veterinarias, Facultad de Veterinaria, Universidade de Santiago de Compostela, Lugo, 27002, Spain. Electronic address: m.cifuentes@usc.es.
Departamento de Fisioloxía, Facultade de Veterinaria, Universidade de Santiago de Compostela, Lugo, 27002, Spain. Electronic address: mmercedes.rodriguez@usc.es.
Departamento de Farmacoloxía, Farmacia e Tecnología Farmacéutica, Facultade de Veterinaria, Universidade de Santiago de Compostela, Lugo, 27002, Spain. Electronic address: luis.botana@usc.es.
Centre for Children's Burns and Trauma Research, Centre for Children's Health Research, School of Biomedical Sciences, Queensland University of Technology, 62 Graham St, South Brisbane, QLD, 4101, Australia.
Faculty of Medicine and Children's Health Research Centre, Centre for Children's Burns and Trauma Research, Centre for Children's Health Research, The University of Queensland, 62 Graham St, South Brisbane, QLD, 4101, Australia.
Centre for Children's Burns and Trauma Research, Centre for Children's Health Research, School of Biomedical Sciences, Queensland University of Technology, 62 Graham St, South Brisbane, QLD, 4101, Australia.
Attention Deficit/Hyperactivity Disorder (ADHD) is associated with a diversity of impairments and Oppositional Defiant Disorder (ODD) is a very frequent comorbidity. Parent Training, as an evidence-ba...
Patients and their families will be screened upon their entry into the Research Center of Impulsivity and Attention (NITIDA) at UFMG-Brazil. Ninety families whose children are male, between 6-12 years...
This clinical trial intends to verify the effects of a new, online, model of an evidence-based intervention, which would allow a wider access in the Brazilian context....
Registered on Brazilian Registry of Clinical Trials (ReBEC). Number: RBR-6cvc85. July 24th (2020) 05:35 pm....
To evaluate whether underlying infertility and mode of conception are associated with childhood behavioral disorders....
Oversampling on fertility treatment exposure using vital records, the Upstate KIDS Study followed 2057 children (of 1754 mothers) from birth to 11 years. Type of fertility treatment and time to pregna...
Children conceived with fertility treatment (34%) did not have an increased risk of attention-deficit/hyperactivity disorder (aRR): 1.21; 95% CI: 0.88, 1.65), or conduct or oppositional defiant disord...
Underlying infertility or its treatment was not associated with risk of attention-deficit/hyperactivity disorder. Observations of increased anxiety or depression require replication....
To assess attachment styles among adolescents (13-16 years) with ADHD or ADHD and oppositional defiant disorders (ODD)....
The Parents and Peers Attachment (IPPA) and the Parent Bonding Questionnaire (PBI) were used in three groups of teenagers raised in biological families: (1) ADHD/ODD group (n = 40), (2) ADHD group (n ...
Parental attachment styles in the area of "Trust", "Communication" and "Alienation" (IPPA), and "Care" and "Control" (PBI) in the ADHD/ODD group differ significantly compared to the control group. Tee...
The attachment style is significantly different in adolescents diagnosed with ADHD and ODD than in adolescents with only ADHD. In the ADHD/ODD group and the ADHD group, unlike in the group of adolesce...
Comparison of the functioning of families of teens (13-16 years) with the diagnosis of attention deficit hyperactivity disorder (ADHD) or ADHD and oppositional defiant disorder (ODD)....
Assessment using the Family Assessment Questionnaire in three groups of adolescents growing up in biological families: (1) ADHD/ODD group (n = 40), (2) ADHD group (n = 40) and (3) group C (control gro...
Mothers, fathers and adolescents from the ADHD/ODD group scored significantly lower in all important aspects of family functioning compared to the control group. In the ADHD group, less favorable moth...
The functioning of families of patients with ADHD and ODD, and families of patients with ADHD significantly differs in all or most of the examined dimensions compared with families of people without d...
The diagnostic criteria for attention deficit hyperactivity disorder (ADHD) reflect the behavioural and functional outcomes of cognitive processes. Historically they have been based on external observ...
The impairment of executive functions (EFs) in attention-deficit/hyperactivity disorder (ADHD) might vary from one individual to another, indicating high heterogeneity. Comorbidity may contribute to t...
This cohort study aimed to examine the association between prenatal exposure to illicit drugs and neurodevelopmental and disruptive behavioral disorders (DBD) in children aged 7-12 years, using data f...
Child-centered play therapy (CCPT) is a practical and recommended non-medication intervention for children with Attention-deficit/hyperactivity disorder (ADHD) but the mechanism in between is unclear....
This study proposed to examine the effectiveness of CCPT on neuropsychological deficits and behavioral symptoms in ADHD....
Participants with ADHD diagnosis were referred from senior child and adolescent psychiatrists, and typical developmental children (TD) were recruited from community as a control group. All participant...
Total 52 participants were recruited (17 with ADHD and 35 typically developed children, TD). The results showed that overall the ADHD groups had worse neuropsychological performance and more behaviour...
Cross-sectional studies have demonstrated associations between screen time and disruptive behavior disorders (conduct disorder and oppositional defiant disorder); however, prospective associations rem...
We analyzed data from the Adolescent Brain Cognitive Development (ABCD) Study (N = 11,875). Modified Poisson regression analyses were conducted to estimate the associations between baseline child-repo...
Participants reported an average of 4 hr of total screen time per day at baseline. Each hour of total screen time per day was prospectively associated with a 7% higher prevalence of conduct disorder (...
Higher screen time was prospectively associated with a higher prevalence of new-onset disruptive behavior disorders. The strongest association was between social media and conduct disorder, indicating...
Caring for children with attention-deficit/hyperactivity disorder (CADHD) is stressful for caregivers. Identifying factors related to parenting stress in caregivers of CADHD can facilitate the develop...